A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Clinical trial NCT07054099 · RECRUITING

Trial details

NCT number: NCT07054099
Sponsor: GC Biopharma Corp
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Varicella (Chickenpox)Chickenpox Vaccine

Start date: 2026-03-17
Primary completion: 2027-08-01
Enrollment: 474

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.